Thrombocytopenia — Low Blood Platelet Count

Thrombocytopenia is defined clinically as a peripheral blood platelet count falling below the lower reference limit, typically less than 150,000 platelets per microlitre of blood. In oncology, it often results from bone marrow suppression secondary to cytotoxic chemotherapy, targeted agents, or broad-field radiotherapy.

It may also occur when malignancies directly infiltrate the bone marrow haematopoietic niche, or through accelerated peripheral destruction via immune-mediated processes or splenic sequestration. Depending on the severity—graded from mild (Grade 1) to life-threatening (Grade 4)—low platelet counts compromise primary haemostasis, elevating the risk of spontaneous haemorrhage.

Detecting thrombocytopenia is essential for preventing dangerous bleeding episodes. When platelet counts drop significantly, medical teams may need to delay upcoming chemotherapy cycles, reduce drug dosages, or postpone planned surgical procedures until the bone marrow recovers. Patients who understand this condition can take practical precautions at home—such as using a soft toothbrush, avoiding contact sports, and steering clear of medications that thin the blood—whilst knowing exactly when to seek urgent clinical attention.

Thrombocytopenia is diagnosed and tracked using a routine Full Blood Count (FBC). In complex cases, a peripheral blood smear, coagulation screen, or bone marrow aspiration and biopsy may be performed to determine whether the issue stems from underproduction or rapid peripheral destruction.

Thrombocytopenia is frequently encountered in haematological cancers such as leukaemia, multiple myeloma, and lymphoma due to marrow infiltration. It also occurs across solid tumours—such as lung, breast, and gastrointestinal cancers—as a side effect of myelosuppressive chemotherapy regimens.

Significant thrombocytopenia often necessitates postponing chemotherapy doses until counts recover above safety thresholds (often 75,000–100,000/μL). Management strategies include platelet transfusions for severe deficits, dose modifications, or occasionally thrombopoietin receptor agonists (TPO-RAs).